These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12684310

  • 1. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
    Chung CL, Chen YC, Chang SC.
    Chest; 2003 Apr; 123(4):1188-95. PubMed ID: 12684310
    [Abstract] [Full Text] [Related]

  • 2. Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
    Chung CL, Yeh CY, Sheu JR, Chen YC, Chang SC.
    Am J Med Sci; 2007 Dec; 334(6):452-7. PubMed ID: 18091367
    [Abstract] [Full Text] [Related]

  • 3. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
    Hua CC, Chang LC, Chen YC, Chang SC.
    Chest; 1999 Nov; 116(5):1292-6. PubMed ID: 10559090
    [Abstract] [Full Text] [Related]

  • 4. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
    Chung CL, Chen CH, Sheu JR, Chen YC, Chang SC.
    Chest; 2005 Aug; 128(2):690-7. PubMed ID: 16100155
    [Abstract] [Full Text] [Related]

  • 5. Proinflammatory cytokines, fibrinolytic system enzymes, and biochemical indices in children with infectious para-pneumonic effusions.
    Chiu CY, Wong KS, Huang JL, Tasi MH, Lin TY, Hsieh SY.
    Pediatr Infect Dis J; 2008 Aug; 27(8):699-703. PubMed ID: 18664985
    [Abstract] [Full Text] [Related]

  • 6. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
    Alemán C, Alegre J, Monasterio J, Segura RM, Armadans L, Anglés A, Varela E, Ruiz E, Fernández de Sevilla T.
    Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
    [Abstract] [Full Text] [Related]

  • 7. [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion].
    Zhu QQ, Sun GY.
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep; 32(9):674-8. PubMed ID: 20079281
    [Abstract] [Full Text] [Related]

  • 8. Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions.
    Lin FC, Chen YC, Chen FJ, Chang SC.
    Clin Immunol; 2005 Aug; 116(2):166-73. PubMed ID: 15897010
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of inflammatory cytokines in malignant and benign pleural effusions.
    Alexandrakis MG, Coulocheri SA, Bouros D, Mandalaki K, Karkavitsas N, Eliopoulos GD.
    Oncol Rep; 2000 Aug; 7(6):1327-32. PubMed ID: 11032938
    [Abstract] [Full Text] [Related]

  • 10. Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
    Yang L, Hu YJ, Li FG, Chang XJ, Zhang TH, Wang ZT.
    Mediators Inflamm; 2016 Aug; 2016():3068103. PubMed ID: 27034588
    [Abstract] [Full Text] [Related]

  • 11. Pathways of fibrin turnover of human pleural mesothelial cells in vitro.
    Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR.
    Am J Respir Cell Mol Biol; 1992 Oct; 7(4):414-26. PubMed ID: 1389210
    [Abstract] [Full Text] [Related]

  • 12. Tumour necrosis factor-alpha and nitric oxide, determined as nitrite, in malignant pleural effusion.
    Agrenius V, Gustafsson LE, Widström O.
    Respir Med; 1994 Nov; 88(10):743-8. PubMed ID: 7846335
    [Abstract] [Full Text] [Related]

  • 13. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
    Hsu LH, Hsu PC, Liao TL, Feng AC, Chu NM, Kao SH.
    BMC Cancer; 2016 Jul 13; 16():463. PubMed ID: 27411914
    [Abstract] [Full Text] [Related]

  • 14. Proinflammatory and antiinflammatory cytokine levels in complicated and noncomplicated parapneumonic pleural effusions.
    Marchi E, Vargas FS, Acencio MM, Sigrist RMS, Biscaro MDA, Antonangelo L, Teixeira LR, Light RW.
    Chest; 2012 Jan 13; 141(1):183-189. PubMed ID: 21680642
    [Abstract] [Full Text] [Related]

  • 15. PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax.
    Zentina D, Stukena I, Krams A, Lejnieks A.
    Medicina (Kaunas); 2019 Sep 04; 55(9):. PubMed ID: 31487930
    [Abstract] [Full Text] [Related]

  • 16. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome.
    Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS.
    Fertil Steril; 1999 Aug 04; 72(2):286-92. PubMed ID: 10438997
    [Abstract] [Full Text] [Related]

  • 17. Changes in cell population and tumor necrosis factor, interleukin-6, and interleukin-8 in malignant pleural effusions after treatment with intrapleural tetracycline.
    Lin CC, Liu CC, Lin CY.
    Am Rev Respir Dis; 1993 Jun 04; 147(6 Pt 1):1503-6. PubMed ID: 8503562
    [Abstract] [Full Text] [Related]

  • 18. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.
    Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A.
    Respirology; 2004 Mar 04; 9(1):81-6. PubMed ID: 14982607
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions.
    Xirouchaki N, Tzanakis N, Bouros D, Kyriakou D, Karkavitsas N, Alexandrakis M, Siafakas NM.
    Chest; 2002 Mar 04; 121(3):815-20. PubMed ID: 11888965
    [Abstract] [Full Text] [Related]

  • 20. Metabolomics Reveals Anaerobic Bacterial Fermentation and Hypoxanthine Accumulation for Fibrinous Pleural Effusions in Children with Pneumonia.
    Chiu CY, Cheng ML, Wong KS, Lai SH, Chiang MH, Tsai MH, Lin G.
    J Proteome Res; 2019 Mar 01; 18(3):1248-1254. PubMed ID: 30757903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.